1. Introduction {#sec1}
===============

Pituitary tumours represent 10--15% of all intracranial tumours. The standardised incidence rate of pituitary tumours is ∼4/1,00,000, with the higher incidence being in females (∼5/1,00,000) ([@bib117], [@bib93], [@bib46]). Pituitary tumours may occur as part of hereditary syndromes (e.g. Multiple Endocrine Neoplasia Type 1 (MEN1) or Type 4 (MEN4)), or as an isolated (non-syndromic) disorder which may be inherited (e.g. Familial Isolated Pituitary Adenomas (FIPA)), or more commonly (\>95%) as non-familial (i.e. sporadic) neoplasms ([@bib131]). Pituitary tumours are also classified according to their hormonal production as: lactotrophinomas (secreting prolactin), that comprise ∼50% of tumours; gonadotrophinomas (secreting follicle stimulating hormone (FSH) or lutenising hormone (LH), but predominantly non-functioning), comprising ∼30% of tumours; somatotrophinomas (secreting growth hormone (GH)), comprising 15--20% of tumours; corticotrophinomas (secreting adrenocorticotropic hormone (ACTH)), comprising 5--10% of tumours; and thyrotrophinomas (secreting thyroid stimulating hormone (TSH)), comprising \<1% of tumours. However, it is important to note that pituitary adenomas may secrete more than one hormone ([@bib69]). Over 99% of pituitary tumours are benign adenomas with \<0.2% being carcinomas that may metastasise ([@bib101]).

To date, over 30 animal models of pituitary tumourigenesis, usually mouse models, have been generated, using gene knockout and over-expression approaches. Evaluation of these models has increased our understanding of pituitary tumour biology and of the roles of oncogenic and tumour suppressor genes. This review will discuss these animal models of pituitary neoplasia, focussing on rodent models, together with the methods used in their generation. In addition, use of a *Men1* mouse model in evaluating approaches to targeted therapies will be reviewed.

2. Pituitary neoplasia models {#sec2}
=============================

Pituitary neoplasia may result from mutations involving either activation of a dominant gain-of-function oncogene, or inactivation of a recessive loss-of-function tumour suppressor gene. These mutations have been discovered by studies of pituitary tumours from patients, or from animal models generated for other disorders. To date, human studies of familial syndromes and sporadic disease have indicated the involvement of \>35 genes in the development and progression of pituitary neoplasias ([Table 1](#tbl1){ref-type="table"}). Animal models harbouring mutations of ∼35% of these genes have been generated, and animal models of mutations in genes not previously implicated in pituitary neoplasia have also been generated, such that over 40 animal models of pituitary neoplasia have been generated, with the majority of these animal models being mutant mice ([Table 2](#tbl2){ref-type="table"}). Many of these models represent human syndromes e.g. MEN1 ([@bib25], [@bib14], [@bib17], [@bib72], [@bib73], [@bib50]) and MEN4 ([@bib63], [@bib83], [@bib37]), as well as representing a range of pituitary neoplasms that include hyperplasia, adenomas and carcinomas ([Table 2](#tbl2){ref-type="table"}). These pituitary tumours may secrete hormones such as prolactin, GH, ACTH, FSH, LH and TSH, or they may be non-secreting, which is also referred to as non-functioning adenomas ([Table 2](#tbl2){ref-type="table"}). These models have been generated using different methods, which will be briefly reviewed below.

2.1. Generation of animal models {#sec2.1}
--------------------------------

Mutant animal models may be generated using: gene deletion (knockouts); over-expression by transgenic expression of wild type or mutant alleles; mutagenesis using chemicals e.g. *N*-ethyl-*N*-nitrosourea (ENU), or radiation; drugs e.g. long-term oestrogen treatment; and the breeding of animals with spontaneously arising abnormalities.

### 2.1.1. Gene deletion models {#sec2.1.1}

Gene deletion by homologous recombination (also referred to as knockout) is one of the most widely used methods to generate specific mouse models. Methods are based on modifying the gene of interest in embryonic stem (ES) cells ([Fig. 1](#fig1){ref-type="fig"}). In conventional knockout models, a vector construct comprising a plasmid or attenuated virus encoding a DNA sequence with homology to the target gene, but carrying a mutated base or bases resulting in loss of the protein, together with a positive selection marker (e.g. *Neo*), flanked by LoxP sites (allowing subsequent excision from selected cells), is introduced into ES cells where it undergoes homologous recombination resulting in stable integration of the mutated gene into the ES cell genome ([@bib78], [@bib49]) ([Fig. 1](#fig1){ref-type="fig"}A). These modified ES cells are then injected into a mouse blastocyst to produce chimeric offspring, and ultimately mice heterozygous for the introduced mutation ([Fig. 1](#fig1){ref-type="fig"}C). These heterozygous mice may then in turn be interbred to produce homozygous mice, providing the mutation is not embryonic lethal ([Fig. 1](#fig1){ref-type="fig"}D). The option of producing either heterozygous or homozygous models can also provide further insights into whether phenotypes are inherited in a dominant or recessive manner. In tumour models this is of particular importance as often patients carry a heterozygous mutation but require a second hit to cause loss of heterozygosity (LOH), and the development of a tumour, for example in patients with MEN1 ([@bib116]). New strategies have been developed to generate mouse knockout models on a large scale. For example, non-targeted gene knockout models have been generated using gene trap ([@bib23], [@bib24]) that comprises a plasmid or virus vector containing a promoter-less selectable marker (e.g. β-galactosidase) flanked by a splice acceptor site and a polyA signal, that when introduced into ES cells randomly inserts into the genome ([Fig. 1](#fig1){ref-type="fig"}B). If the vector inserts into the intron of a gene then the splice acceptor generates fusion transcripts of the selection marker with the exons upstream in the endogenous gene, thereby leading to truncation and knockout of the protein ([@bib110]). As the gene trap randomly inserts into the ES cell genome sequencing analysis can be performed to identify the site of gene trap insertion and therefore to confirm the gene knockout. More recently a targeted gene trapping method has been developed in which the vector also contains regions homologous to the gene of interest ([@bib23], [@bib24], [@bib41]).

In conventional or gene trap knockout models, generation of homozygous mice may result in embryonic lethality, as illustrated by *Men1*^−/−^ mice ([@bib25], [@bib14], [@bib15], [@bib72], [@bib73], [@bib50], [@bib39], [@bib67]), indicating that the encoded protein, menin, plays a pivotal role in embryonic development. This embryonic lethality can be overcome by use of conditional knockout models that are tissue or cell type specific. These models can be produced by utilising *Cre*-LoxP or FLP-*Frt* systems ([Fig. 2](#fig2){ref-type="fig"}), whereby the genomic region of interest is flanked by LoxP or flippase (FLP) recombination target (Frt) sites. These sites are recognised by Cre recombinase or FLP enzymes, respectively, which excise the DNA sequence floxed by the LoxP or Frt sites ([@bib80]). This method of generation requires two mouse lines, one line containing the genomic region of interest flanked by LoxP or Frt and another line expressing the tissue-targeted Cre or FLP, which are generated by transgenic methods (see [Section 2.1.2](#sec2.1.2){ref-type="sec"}). These mice are then crossed to generate mice expressing both the flanked construct and the recombinase. Tissue targeting of the Cre or FLP is achieved by restricting their expression using a tissue-specific promoter, for example rat growth hormone releasing hormone receptor (*Ghrh* receptor) to restrict Cre expression to the pituitary ([@bib132]). Inducible models that allow control over the timing of gene knockout can also be generated using fusion proteins. For example, a modified ligand-binding domain of the oestrogen receptor can be fused to Cre, which only upon administration of tamoxifen (which binds the oestrogen receptor), translocates to the nucleus and excises the floxed DNA region, allowing knockout of the gene at a chosen time point during the animals life span ([@bib39]).

### 2.1.2. Knockin and transgenic models {#sec2.1.2}

Knockin and transgenic models can be generated to assess gain-of-function mutations or constitutive over-expression of genes, respectively. The targeted knockin approach is similar to the conventional knockout method described above and in [Fig. 1](#fig1){ref-type="fig"}, except that the introduced construct is designed to cause gene over-expression, for example by incorporation of a gain-of-function mutation ([@bib49], [@bib90]). The transgenic model differs from the knockin model in that a cDNA construct, containing cDNA of either an endogenous gene (i.e. wild type construct) or a gene of interest carrying a desired mutation, and an appropriate promoter and poly(A) sequence, is injected into the pronucleus of fertilised mouse oocyte, which is implanted into a pseudopregnant female ([@bib51]). This transgene can randomly insert into the genome, thereby introducing additional genetic information, which upon transcription results in over-expression of the inserted wild type or mutant gene ([@bib90], [@bib47]). Transgenic approaches can therefore provide a tool to examine dominant negative effects of mutant proteins, as often mutations are heterozygous and therefore patients express both mutant and wild type proteins.

### 2.1.3. Gene editing methods {#sec2.1.3}

Recent advances in generating animal models involve the technique of genome editing. Gene editing can be achieved by multiple methods including the use of zinc finger nucleases and transcription activator-like effector nucleases (TALENs). The most recently developed method of genome editing, however, is that using the clustered regularly interspaced short palindromic repeats (CRISPR)-CRISPR associated (Cas) system ([@bib103]). The CRISPR/Cas system utilises a prokaryotic adaptive immune response mechanism in which RNA transcribed from small segments of plasmids or viral genomes that have been incorporated as CRISPRs during an earlier infection, are used to target Cas9 proteins to new infections where they cleave the DNA and therefore inactivate invading plasmids or viruses ([@bib103]). This system can be used to target Cas9 proteins to specific DNA regions by developing a synthetic targeting RNA template, to cause double strand breaks, which depending on the DNA repair mechanisms employed, allows both the generation of knockout and knockin models ([Fig. 4](#fig4){ref-type="fig"}). Mouse models can be produced by either editing an ES cell or by direct microinjection into a zygote, with the advantage that multiple genes can be targeted in parallel, making the generation of, for example double knockout mice more efficient as it negates the need for multiple breeding cohorts ([@bib126]).

### 2.1.4. Chemical or radiation induced mutagenised models {#sec2.1.4}

Chemicals and radiation can induce alterations in the DNA sequence, which can lead to either gain-of-function (hypermorphic), loss-of-function (hypomorphic) or haploinsufficiency of inherited mutations. The alkylating agent *N*-ethyl-*N*-nitrosourea (ENU) is the most potent mutagen in mice, introducing point mutations via transfer of the ENU alkyl group to DNA bases, and thereby causing mispairing during DNA replication ([@bib90], [@bib2]). The ENU is injected into male mice to mutagenise sperm and allow the mutations to be inherited, and offspring assessed for both genetic and phenotypic differences ([Fig. 3](#fig3){ref-type="fig"}). For screening genetic differences, archives of DNA can be examined for mutations in a gene of interest ([@bib2]). For phenotypic screening, the offspring of the mutagenised mice are assessed using biochemical, morphological and behavioural tests and then the DNA sequenced to elucidate novel genes associated with disease ([@bib2], [@bib13]).

### 2.1.5. Spontaneously occurring mutations {#sec2.1.5}

Phenotypes can also occur spontaneously in animal models, for example due to either naturally occurring mutations, or viral incorporation. This is especially apparent in neoplasia models, and some strains of mice (e.g. C~3~H) and rats (e.g. Sprague--Dawley) have been reported to have a much higher tumour incidence, compared to other strains ([@bib31], [@bib106], [@bib97], [@bib107], [@bib82], [@bib20]). Spontaneous models however are generally less predictable than those specifically generated.

### 2.1.6. Non-genetic methods {#sec2.1.6}

Non-genetic methods have also been used to generate models of pituitary neoplasia. These include long-term hormone administration to induce tumour development, for example oestrogen treatment of ovariectomised rats ([@bib82], [@bib129], [@bib130]) and injection of carcinogenic agents, for example cadmium (an element able to mimic oestrogen) to induce the development of multiple tumour types ([@bib124]). The use of chemical carcinogens is advantageous as they provide mechanistic insights into environmental factors contributing to tumour development. There are however environmental concerns with their use, and reproducibility.

### 2.1.7. Animal model repositories {#sec2.1.7}

Conventional gene knockout, gene knockin and transgenic methods have been successful in generating models of pituitary neoplasia. Many of these models are available from repositories, as live mice, for example through the European Mouse Mutant Archive (EMMA; Europe; <http://strains.emmanet.org/>), the Wellcome Trust Sanger Institute (UK; <https://www.sanger.ac.uk/resources/mouse/>) or Jackson Laboratory (USA; <http://jaxmice.jax.org/>). These repositories also have available mutagenised ES cell clones, to establish mouse models. Information on the models and availability of ES cells can be found from, for example, the International Mouse Phenotyping Consortium (IMPC; <https://www.mousephenotype.org/>). In addition, ENU mutagenised sperm and live mice are available from MRC Harwell (UK; <http://www.har.mrc.ac.uk/>).

2.2. Mouse pituitary neoplasia models {#sec2.2}
-------------------------------------

The majority (∼90%) of existing pituitary neoplasia models have been established using mice ([Table 2](#tbl2){ref-type="table"}). These models have been predominantly generated using gene knockout and over-expression methods.

### 2.2.1. Knockout models {#sec2.2.1}

To date, homologous deletions of 10 different genes, which are *Men1*, *Cdkn1b*, *Prkar1a*, *Rb*, *Cdkn2b* (encoding p19), *Drd2*, *Cdkn2c* (encoding p18), *Aip*, *Prl* and *Prlr*, have been reported to yield mouse knockout models for pituitary tumours. Of these 10 genes, 5 (*Men1*, *Cdkn1b*, *Prkar1a*, *Cdkn2b* and *Aip*) are tumour suppressors that are associated with human familial disorders with pituitary tumours. Thus, *Men1*^+/−^ mice develop tumours consistent with MEN1 ([@bib25], [@bib14], [@bib15], [@bib17], [@bib72], [@bib73], [@bib50]), which is characterised by the occurrence of tumours of the parathyroid glands (in ∼95% of patients), pancreatic islets (in ∼40% of patients) and the anterior pituitary (in ∼30% of patients) ([@bib116]). The majority of pituitary adenomas in MEN1 patients are prolactinomas, followed by somatotrophinomas, corticotrophinomas and non-functioning adenomas ([@bib116]). Pituitary adenomas occurring in individuals with MEN1 are generally larger and more aggressive than sporadic tumours, and 2--3% of sporadic pituitary adenomas have *MEN1* mutations ([@bib116], [@bib119], [@bib75]). The *MEN1* gene is located on human chromosome 11q13 and contains 10 exons, with exon 1 non-coding. More than 1000 different germline mutations have been found in the coding region and splice sites of the *MEN1* gene, with the majority (75%) predicted to yield truncated forms and loss of its encoded protein, menin ([@bib66]). The knowledge of these mutations, and that loss of menin can cause tumour development, has led to the generation of a number of *Men1* mouse models. In mice the *Men1* gene is located on chromosome 19, but has an exon-intron organisation similar to that of the human gene (i.e. 10 exons), and the mouse menin protein shows 97% homology with the human menin protein ([@bib113]). Six different mouse models for MEN1 have been generated, consisting of 4 conventional heterozygous and 2 conditional homozygous *Men1* knockouts, and 5 of these 6 models develop pituitary adenomas ([@bib25], [@bib14], [@bib15], [@bib17], [@bib72], [@bib73], [@bib50], [@bib18], [@bib26]). The 4 conventional *Men1*^+/−^ models consist of 1 with deletion of exons 3--8 ([@bib25]), 1 with deletion of the transcriptional start site and exon 2 ([@bib17], [@bib72], [@bib73]), 1 with deletion of exon 3 ([@bib14], [@bib15]) and 1 with deletion of exons 1 and 2 ([@bib50]). In each of these models pituitary tumours occurred in 26--45% of mice by 18 months of age, with prolactin-expressing tumours being the most common. For each of the conventional models homozygous (*Men1*^−/−^) mice were embryonic lethal. To study the effects of complete loss of menin in specific tissues and organs, 2 conditional models have been generated. In one model, mice with *Men1* exons 3--8 floxed with LoxP were crossed with mice expressing Cre under the control of the rat insulin promoter, which as well as being expressed in pancreatic islets is weakly expressed in the pituitary. This resulted in the occurrence of pancreatic beta cell tumours, and pituitary adenomas which immunostained for prolactin in up to 58% of mice ([@bib26]). In another model exon 3 of *Men1* was floxed with LoxP sites and crossing this line with mice expressing *Rip-Cre*, was reported to result only in the development of pancreatic tumours ([@bib14]).

Mouse models that have also been generated for other pituitary adenoma associated human disorders include: MEN4; Carney Complex; Acromegaly/gigantism and FIPA. Thus, *Cdkn1b*^+/−^ mice develop tumours consistent with MEN4, which is characterised by the occurrence of pituitary and parathyroid tumours in association with other endocrine tumours (e.g. of gonads and adrenals) ([@bib63], [@bib83], [@bib38]). *Prkar1a*^+/−^ mice develop tumours consistent with Carney Complex syndrome, which is characterised by increased occurrence of different tumour types including myxomas, schwannomas, and endocrine tumours, which include somatotrophinomas, adrenal cortical tumours, sertoli cell tumours, ovarian cysts and thyroid follicular adenomas ([@bib132]). *Cdkn2c*^+/−^ mice develop tumours consistent with acromegaly/gigantism, due to GH secreting tumours ([@bib40]). The phenotypic features of *Aip*^+/−^ mice are similar to that observed in FIPA patients, who have *AIP* mutations and predominately develop GH secreting adenomas, although some patients may also develop PRL or ACTH secreting and non-functioning adenomas ([@bib68], [@bib120], [@bib94]). These models provide valuable resources to study the mechanisms causing pituitary tumours. For example, investigation of the *Aip*^+/−^ mouse model has revealed that the associated pituitary tumours have activation of a hypoxic response, with induction of HIF-1α expression, and that signalling through the HIF-1α binding partners aryl hydrocarbon receptor nuclear translocator (ARNT) and ARNT2 is a key factor in the development of pituitary tumours, after loss of Aip ([@bib94]).

Studies of other mouse models deleted for genes that were not previously known to be associated with the development of pituitary tumours in man have revealed roles for such genes, which includes *Rb*, *Cdkn2b*, *Drd2*, *Prl* and *Prlr*, in pituitary tumourigenesis. The Rb protein is a tumour suppressor with an integral role in cell cycle progression, controlling the passage from G1 into S phase ([@bib127]) and ∼90% of patients with a heterozygous germline *RB* mutation develop childhood onset retinoblastoma. However, *Rb*^+/−^ mice were found not to develop retinoblastoma, but instead to develop pituitary carcinoma, and therefore provide a valuable model for studying the development of pituitary carcinomas ([@bib55], [@bib122], [@bib123]). Moreover, use of the FLP-frt system to generate conditional *Rb* knockout mice has revealed that mice null for *Rb* specifically in the pituitary, rapidly develop melanotroph tumours ([@bib122]), and showed that Rb loss is an initiating step in carcinogenesis, leading to inappropriate entry into S phase of the cell cycle ([@bib122]). In addition, use of the Cre-LoxP system to knockout *Rb* in the mouse pituitary proopiomelanocortin (POMC) cell lineages (corticotrophs and melanotrophs), together with expression of firefly luciferase under the control of the POMC promoter has generated a model allowing real time imaging of tumour growth, using bioluminescence, which allows accurate evaluation of the efficacy novel therapies including the chemotherapeutic action of doxorubicin ([@bib123]). Finally, the role of p19, encoded by *Cdkn2b*, as a tumour suppressor in regulating pituitary anterior lobe proliferation has been revealed by a conventional knockout mouse model of *Cdkn2b*, as *Cdkn2b*^−/−^ mice developed multiple tumour types including PRL, GH and FSH secreting pituitary adenomas ([@bib10]).

### 2.2.2. Over-expression and knockin models {#sec2.2.2}

Over-expression models have been generated to investigate the roles: of hormones in pituitary tumourigenesis, e.g. over-expression of the growth hormone releasing hormone (*Ghrh*) gene in mice resulted in pituitary adenomas that led to excessive GH secretion ([@bib7]); and of oncogenes and tumourigenic viruses. Thus, over-expression of some viral proteins, such as Simian virus 40 (SV40) T antigen, which have been termed 'oncoviruses' as infection of tissues can lead to tumour development, generated a mouse model with somatotrophinomas ([@bib111]), and over-expression of a polyoma early region promoter linked to a cDNA encoding polyoma large T antigen (PyLT), in mice, induced development of ATCH-secreting pituitary tumours, thereby providing a model for Cushing\'s disease ([@bib53]). Transgenic over-expression of cortocotropin releasing hormone (*Crh*) in mice has also generated a model of Cushing\'s disease ([@bib112]), and an ENU induced mouse mutant with a *Crh* promoter mutation has been reported to develop Cushing\'s Syndrome ([@bib13]). In addition, use of constructs containing promoters of genes expressed in the pituitary has facilitated generation of targeted models. Thus, mice harbouring a transgene with the SV40 early gene encoding large T antigen ligated to the POMC promoter, developed melanotroph tumours ([@bib74]), and mice harbouring the SV40 T antigen targeted to gonoadotroph cells using the follicle stimulating hormone β (Fshβ) promoter, generated a model of non-functioning adenomas ([@bib65]).

The role of the pituitary transforming gene (*Pttg*) has also been established by the use of tissue-specific transgenic over-expression mouse models ([@bib30], [@bib1]). *Pttg*, which was first identified from rat pituitary tumour cells ([@bib86]), and subsequently shown to be over-expressed in human pituitary tumours ([@bib99]), encodes a securin protein that plays a role in cell transformation, aneuploidy, apoptosis and tumour microenvironment communication ([@bib121]). Mice with targeted pituitary *Pttg* over-expression, driven by the pituitary specific alpha subunit glycoprotein promoter have been reported to develop focal pituitary hyperplasia, whilst mice with *Pttg* inactivation have pituitary hypoplasia ([@bib30]), consistent with a pituitary tumourigenic role of *Pttg*.

The tumourigenic role of the High mobility group A (*Hmga*) genes has also been investigated by transgenic over-expression in mouse models. HMGA proteins are architectural transcription factors as they regulate the assembly of complexes important for gene transcription ([@bib36]). The two HMGA genes, *HMGA1* and *HMGA2*, are expressed at high levels during embryogenesis, and in some human carcinomas, but are not expressed in the majority of adult normal tissues ([@bib36]). The oncogenic potential of the HMGA genes in pituitary tumourigenesis has been evaluated by the generation of global transgenic over-expression mouse models ([@bib35], [@bib34]). Over-expression of either *Hmga1* or *Hmga2* resulted in the development of mixed somatotroph/lactotroph pituitary adenomas by 16 months of age ([@bib35], [@bib34]), and Hmga2 has been reported to enhance E2F1 activity, which is usually repressed by Rb to prevent progression through the cell cycle ([@bib36]).

Knockin mouse models of the cyclin dependent kinases (CDKs) and cyclin dependent kinase inhibitors (CKIs) have been reported to develop pituitary tumours ([@bib108], [@bib16], [@bib98]). The CKIs, p16, p15, p18 and p19, inhibit the activity of the CDKs CDK4 and CDK6, thereby preventing phopsphorylation of Rb, and G1 to S phase transition ([@bib22]), and a mouse with a *Cdk4* point mutation (Arg24Cys) that resulted in insensitivity to the CKIs ([@bib108]), developed tumours of the pituitary, pancreas and testes ([@bib108]). In addition, a mouse with a mutation (Ser10Ala) of *Cdkn1b*, which encodes p27, a member of the p21 family of CKIs that abrogated its ability to bind CDKs ([@bib16]), resulted in the development of pituitary adenomas ([@bib16]). Moreover, one of the target cyclin complexes of p27 is cyclin E-CDK2, and a transgenic over-expression mouse model has indicated that cyclin E expression in the POMC lineage is sufficient to cause cells to re-enter the cell cycle and initiate pituitary adenoma growth ([@bib98]). These mouse models, which highlight the critical role of the G1 checkpoint in pituitary tumourigenesis, provide pre-clinical models for assessing the efficacy of small molecule inhibitors of cyclin dependent kinases that are being developed for the treatment of cancers ([@bib22]).

### 2.2.3. Double mutant models {#sec2.2.3}

Studies of double mutant mouse models have provided important *in vivo* mechanistic insights into cell cycle regulation during pituitary tumour development, and the progression of benign pituitary adenomas to carcinomas. Thus, 12 double mutant mouse models comprising: *Pttg*/*Rb*^+/−^; *Rb*^+/−^/*Ini1*^+/−^; *Rb*^+/−^*/Arf*^−/−^; *Rb*^+/−^/*p53*^−/−^; *Cdk4*^*R*/*R*^/*Cdkn1b*^−/−^; CyclinE/p27^−/−^; p18^−/−^/p27^−/−^; p18^−/−^/αSU^−/−^; Ink4c^−/−^/Arf^−/−^; *Men1*^+/−^*/Rb*^+/−^; *Men1*^+/−^/*Cdk2*^−/−^ and *Men1*^+/−^/*Cdk4*^−/−^, have been generated ([Table 2](#tbl2){ref-type="table"}). Five of these double mutant mouse models utilised *Rb*^+/−^ mice to investigate co-operative pathways in pituitary tumourigenesis, and revealed that: over-expression of the pituitary hyperplasia-promoting gene *Pttg* in combination with *Rb*^+/−^ increases the volume and prevalence of anterior pituitary tumours, whereas loss of *Pttg* expression, as occurring in *Pttg*^−/−^ mice can protect against tumours initiated by loss of Rb ([@bib30], [@bib21]); Rb is epistatic to a member of the SW1/SNF chromatin remodelling complex, Ini1, in tumour suppression ([@bib48]); loss of the tumour suppressor proteins p53 or Arf (that stabilises p53 protein), as in occurring in p53^−/−^ or Arf^−/−^ mice, in combination with Rb^+/−^ accelerated pituitary tumour development ([@bib52], [@bib118]); and *Men1*^+/−^/*Rb*^+/−^ mice did not have significant differences in the occurrence or age of onset of pituitary, or other tumours, when compared to *Men1*^+/−^ or *Rb*^+/−^ mice ([@bib72], [@bib73]), thereby indicating that menin and Rb do not have an additive effect and are therefore likely to function in a common pathway to suppress tumour development. The remaining 7 double mutant models have utilised loss of CKIs from both the INK4 and p21 family to investigate the interaction between different cyclins, CDK, CKIs and their substrates (Rb) in the pituitary ([@bib40], [@bib98], [@bib109], [@bib136], [@bib71]). Thus, *Cdk4*^*R*/*R*^/*Cdkn1b*^+/−^ and *Cdk4*^*R*/*R*^/*Cdkn1b*^−/−^ mice, which would be null for p27 and have a mutant of CDK4 that renders it insensitive to INK4 inhibitors, have been reported to develop pituitary tumours with complete penetrance and a short latency, thereby indicating that there is co-operativity between p27 and CDK4 ([@bib109]). Such co-operativity was not identified to occur between p18 and CDK4 in similar studies using the *Cdk4*^*R*/*R*^*/Cdkn2c*^−/−^ mouse model ([@bib109]). These results indicate that p27 may have a wider function that just inhibiting CDK4 activity, which has previously been considered to be the predominant function of p18. Moreover, it has also been reported that up-regulation of cyclin E (using a transgene construct under the control of the POMC promoter, *Tg*-*PCE*) and knockout of p27 (*Cdkn1b*^−/−^) in the *Tg*-*PCE*/*Cdkn1b*^−/−^mouse model, leads to increased pituitary adenoma incidence and frequency ([@bib98]) and that p27 and p18 mediate two separate pathways to collaboratively suppress tumourigenesis ([@bib40]). *Men1*^+/−^/*Cdk4*^−/−^ mice have been demonstrated to not develop any tumours, whereas *Men1*^+/−^/*Cdk2*^*−/−*^ mice develop pituitary and pancreatic tumours comparable to those in *Men1*^+/−^ only mice. ([@bib45]). This indicates that Cdk4 activity is important for *Men1*-associated tumourigenesis to occur, and that menin may predominantly suppress cell cycle progression through the INK4-Cdk4/6-cyclin D-pRb pathway. Overall, these studies of mutant mouse models with targeted disruption of the cell cycle regulating proteins have provided mechanistic insights in pituitary tumourigenesis.

2.3. Rat pituitary neoplasia models {#sec2.3}
-----------------------------------

Some rat strains, including Sprague Dawley rats, are more prone to pituitary tumour development ([@bib106], [@bib107], [@bib20]). For example, a variant of the MEN syndromes, termed MENX, was discovered to occur spontaneously in Spague--Dawley rats, which developed parathyroid adenomas, pancreatic islet cell hyperplasia, thyroid c-cell hyperplasia, bilateral phaeochromocytomas and paragangliomas ([@bib77]). MENX was inherited as an autosomal recessive disorder and the rats were found to have a germline homozygous frameshifting insertion mutation in the *Cdkn1b* gene ([@bib42]). Studies in patients with MEN1-like tumours, but without *MEN1* mutations, revealed some to have *CDKN1B* mutations. To date 10 different MEN4-associated mutations of *CDKN1B* have been reported, and the MEN4 patients have parathyroid tumours in association with pituitary adenomas and other tumours of the gonads, adrenals, thyroid and kidney ([@bib116], [@bib85]).

Rat models of pituitary neoplasia have also been generated by implanting tumour cells or using drugs. Thus, a rat model for Cushing\'s syndrome was generated by implanting a medullary thyroid carcinoma cell line, which stably over-expressed CRH, into WAG/Rij rats ([@bib6]). Exposure of these rats to elevations in circulating CRH, increased anterior pituitary cell proliferation and circulating ACTH levels ([@bib6], [@bib7]). In addition, a rat model for lactotrophinomas was generated by long-term administration of oestrogens to the F344 and Holtzmon strains ([@bib129], [@bib130]). Such susceptibility to oestrogen treatment in inducing pituitary tumours in rats varies between strains. For example, oestrogen treatment has been shown to differ between strains, with F344 female rats the most susceptible ([@bib82], [@bib129], [@bib130]), and with Wistar-Kyoto rats not developing pituitary tumours upon oestrogen treatment due to lack of lactotroph cell proliferation ([@bib82]). Oestrogens are known to stimulate expression of IGF-1, which leads to increased proliferation. However in Wistar-Kyoto rats the response to IGF-1 was reduced, with IGF-1 target gene expression (*Wnt4*, *Stc1*, *Mybl1* and *Myc*) attenuated or abolished ([@bib82]), and this may explain the lack of lactotroph cell proliferation following oestrogen treatment in Wistar-Kyoto rats.

2.4. Zebrafish pituitary neoplasia model {#sec2.4}
----------------------------------------

A zebrafish model that develops corticotroph adenomas has been generated by utilising transgenic expression of the *Pttg* gene that is targeted specifically to the pituitary POMC lineages ([@bib70]). This study illustrates that zebrafish models for pituitary tumours can be generated, and opens the way to utilising additional methods for the study of pituitary tumourigenesis. Thus, zebrafish knockout models for pituitary tumours could be generated by using morpholino oligomers, which are antisense oligomers that bind complementary messenger RNAs thereby blocking gene expression and leading to gene knockdown ([@bib5]). In addition, ENU mutagenesis can be used to generate hypermorphic or hypomorphic phenotypes in zebrafish ([@bib105]). Studies in zebrafish offer many advantages, such as a high throughput platform for assessing gene abnormalities and for drug efficacy studies, as demonstrated by a study that evaluated the use of the cell cycle inhibitor R-roscovitine for the treatment of corticotroph tumours, the results of which were subsequently confirmed in a mouse model ([@bib70]).

3. Use of the Men1^+/−^ mouse for evaluating novel therapies {#sec3}
============================================================

Mouse models for pituitary tumours have provided pre-clinical models for evaluating new therapies for pituitary tumours. This is illustrated by the use of the *Men1* mouse model, which has been used to assess the role of *Men1* gene replacement therapy and a monoclonal antibody to the vascular endothelial growth factor (VEGF) ([@bib125], [@bib64]). The tumour suppressor role of menin, encoded by *Men1*, suggested that restoration of menin expression in tumours would reduce proliferation. Indeed, gene replacement therapy using an adenoviral vector containing *Men1* cDNA that was delivered directly to the pituitary tumours of *Men1*^+/−^ mice, restored menin expression in the pituitary tumours and reduced their proliferation, without significant adverse effects or increased mortality ([@bib125]). These findings indicate that viral delivery of *MEN1* may be a potential treatment for pituitary and other neuroendocrine tumours associated with MEN1 mutations. Pituitary tumours, in common with other neoplasms, have increased angiogenesis, and angiogenic pathways that can be targeted by monoclonal antibodies to VEGF. Indeed, the monoclonal antibody G6-31 has been reported to inhibit VEGF-induced pituitary tumour growth in conventional *Men1*^+/−^ mice ([@bib64]). Such mouse models therefore provide an important resource for the pre-clinical evaluation of novel therapies for pituitary tumours.

4. Conclusion {#sec4}
=============

Studies of animal models of pituitary neoplasias have helped to advance our knowledge about the biological mechanisms of pituitary tumourigenesis. Thus, these models, predominately in mice, which have been generated by a number of approaches including gene knockout and over-expression of genes, have provided novel insights into the regulation of the cell cycle and its dysfunction in pituitary tumourigenesis. In addition, they provide pre-clinical models for the evaluation of novel and emerging therapies.
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![Gene knockout methods using embryonic stem (ES) cells. A Totipotent ES cells are isolated from the inner cell mass of a blastocyst from a wild type mouse and cultured. B Targeted or non-targeted vectors are introduced into the genome of the ES cells. ES cells in which homologous recombination or random integration and i.e. gene knockout, has occurred are selected using incorporated markers (e.g. Neo). C Selected ES cells are injected into a blastocyst obtained from a different strain to that in step A, and implanted into a pseudopregnant female, which is the same strain as the injected blastocyst. This results in chimeric offspring containing genetic information from both the manipulated ES cells of the original mouse strain and genetic information of the second blastocyst/pseudopregnant female of a different strain. To generate offspring heterozygous for the gene knockout, chimeric offspring are bred with wild type mice. D Heterozygous offspring can be interbred to generate homozygous knockout mice. m-mutated allele; + -- wild type allele.](gr1){#fig1}

![Conditional gene knockout. Gene knockout models can be generated using the FLP-Frt or Cre-LoxP systems. This requires the generation of two constructs: 1) a construct containing Frt or LoxP recognition sites inserted into the intron sequences flanking the genomic region to be knocked out; and 2) a construct containing a FLP or Cre recombinase under the control of a tissue-specific promoter. These constructs are introduced into two different mouse strains using knockin/transgenic over-expression methods, to generate one mouse expressing the Frt/LoxP flanked genomic sequence in all tissues, and one mouse expressing FLP/Cre recombinase in a specific organ e.g. pituitary. These two mouse lines are then bred to generate a mouse containing both the Frt/LoxP flanked genomic sequence and the tissue-specific recombinase. In FLP/Cre-expressing tissues e.g. pituitary, the FLP/Cre binds to its target Frt/LoxP sites and catalyses recombination of the DNA, leading to excision of the genetic material contained between the target sites.](gr2){#fig2}

![N-ethyl-N-nitrosourea (ENU) mutagenesis. ENU is a chemical mutagen that induces point mutations via transfer of its ethyl group (CH~3~) to guanine residues, which in turn causes mispairing during DNA replication. ENU is injected into male mice where it causes mispairing during spermatogenesis, and therefore induces mutations into sperm DNA. Mutagenised mice are mated with female mice of the same strain to generate offspring that have inherited the introduced mutations. Genetic and phenotypic screens are performed to characterise the mutation. m-mutated allele; +--wild type allele.](gr3){#fig3}

![Gene editing using CRISPR/Cas. The CRIPSR/Cas system requires three components: a CRISPR-associated nuclease, for example Cas9; a single guide RNA (SgRNA) consisting of a guide sequence that binds the target DNA, a scaffold sequence for Cas9 binding and a terminating hairpin; and for gene knockin an oligo template containing the sequence to be inserted. The Cas9 is targeted to a specific genomic site by the SgRNA, where it induces a double strand break. In the absence of a repair template this break is repaired by non-homologous end joining, an error prone mechanism that leads to insertion/deletion (indel) mutations, which in turn cause frameshifts and the occurrence of premature stop codons, thereby leading to gene knockouts. If a DNA repair template is present the double strand break is repaired by a homology-driven repair mechanism, using this template, therefore genetic information can be knocked-in by including, for example, gain-of-function point mutations in the inserted template.](gr4){#fig4}

###### 

Genetic abnormalities identified from human studies to be associated with pituitary neoplasias.

  Gene                                                        Tumour type/Syndrome                                         Gene defect                                                                   Reference
  ----------------------------------------------------------- ------------------------------------------------------------ ----------------------------------------------------------------------------- ------------------------
  *AIP*                                                       FIPA                                                         Germline inactivating mutation                                                ([@bib11])
  Young onset sporadic pituitary macroadenomas                                                                                                                                                           
  *BMP-4*                                                     Corticotrophinomas                                           Gene down-regulation                                                          ([@bib44])
  Somatotrophinomas                                           Gene over-expression                                                                                                                       
  Prolactinomas                                               Gene over-expression                                                                                                                       
  *CASP8*                                                     Functioning and non-functioning adenomas                     Methylation mediated gene silencing                                           ([@bib12])
  *CCNA2*                                                     MEN1 patients without *MEN1*, *CASR* or *HRPT2* mutations    Gene over-expression                                                          ([@bib3])
  *CCNB1*                                                     MEN1 patients without *MEN1*, *CASR* or *HRPT2* mutations    Gene over-expression                                                          ([@bib3])
  *CCNB2*                                                     MEN1 patients without *MEN1*, *CASR* or *HRPT2* mutations    Gene over-expression                                                          ([@bib3])
  *CCND1*                                                     Non-functioning adenomas                                     Gene over-expression                                                          ([@bib58])
  *CCNE1*                                                     Cushing\'s syndrome                                          Gene over-expression                                                          ([@bib58], [@bib56])
  MEN1 patients without *MEN1*, *CASR* or *HRPT2* mutations                                                                                                                                              
  *CDH1*                                                      Somatotrophinomas with prominent fibrous bodies              Methylation-mediated gene silencing                                           ([@bib134])
  *CDH13*                                                     Functioning and non-functioning adenomas                     Methylation-mediated gene silencing, correlating with tumour aggressiveness   ([@bib92])
  *CDKN1A*                                                    Functioning and non-functioning adenomas                     Gene down-regulation                                                          ([@bib54])
  *CDKN1B*                                                    MEN4 patients                                                Germline inactivating mutation                                                ([@bib88])
  *CDKN2A*                                                    Functioning and non-functioning adenomas                     Methylation-mediated gene silencing                                           ([@bib134])
  *CDKN2B*                                                    Functioning and non-functioning adenomas                     Methylation-mediated gene silencing                                           ([@bib134])
  *CDKN2C*                                                    Functioning and non-functioning adenomas                     Methylation-mediated gene silencing                                           ([@bib134])
  *DAPK* family                                               Functioning and non-functioning adenomas                     Loss of expression                                                            ([@bib104])
  *FGFR2*                                                     Functioning adenomas                                         Methylation-mediated gene silencing                                           ([@bib135])
  *FGFR4*                                                     Functioning adenomas                                         Constitutively phosphorylated                                                 ([@bib33])
  *GADD45B*                                                   Gonadotrophinoma                                             Gene silencing                                                                ([@bib81])
  *GADD45G*                                                   Functioning, but more commonly in non-functioning adenomas   Gene silencing                                                                ([@bib134])
  *GNAS*                                                      Somatotrophinomas                                            Mutations detected                                                            ([@bib76])
  *HMGA*-1                                                    Prolactinomas                                                Gene over-expression                                                          ([@bib29])
  *HMGA*-2                                                    Prolactinomas                                                Gene over-expression                                                          ([@bib36])
  *LGALS3*                                                    Lactotrophinomas                                             Gene over-expression                                                          ([@bib96])
  Corticotrophinomas                                                                                                                                                                                     
  *MEG3*                                                      Non-functioning adenomas                                     Methylation-mediated gene silencing                                           ([@bib133])
  *MEN1*                                                      MEN1                                                         Inactivating mutations and gene deletions                                     ([@bib115])
  Young onset sporadic pituitary adenomas                                                                                                                                                                
  *MGMT*                                                      Carcinomas                                                   Methylation-mediated gene silencing                                           ([@bib134])
  *PLAGL1*                                                    Non-functioning adenomas                                     Methylation-mediated gene silencing                                           ([@bib84])
  *PRKAR1A*                                                   Somatotrophinomas                                            Gene down-regulation                                                          ([@bib62])
  Non-functioning adenomas                                                                                                                                                                               
  *PTAG*                                                      Adenomas (subtype not defined)                               Methylation-mediated gene silencing                                           ([@bib9])
  *PTTG1*                                                     Functioning and non-functioning adenomas                     Gene over-expression                                                          ([@bib100])
  *RAS* family                                                Functioning and non-functioning adenomas                     Activating mutations                                                          ([@bib59])
  *RASSF1*                                                    Functioning and non-functioning adenomas                     Methylation-mediated gene silencing                                           ([@bib91])
  *RASSF3*                                                    Somatotrophinomas                                            Methylation-mediated gene silencing                                           ([@bib89])
  *RB1*                                                       Aggressive adenomas                                          Rare inactivating mutations, methylation-mediated gene silencing              ([@bib87])
  Carcinoma                                                                                                                                                                                              
  *SOCS1*                                                     Somatotrophinomas                                            Methylation-mediated gene silencing                                           ([@bib19])
  Corticotrophinomas                                                                                                                                                                                     
  Non-functioning adenomas                                                                                                                                                                               
  *SOX2*                                                      Early onset pituitary adenomas                               Rare gene deletion                                                            ([@bib4])
  *TP53*                                                      Carcinoma                                                    Rare inactivating mutations                                                   ([@bib114]) ([@bib60])
  Atypical corticotrophinoma                                  Rare inactivating mutation in one patient                                                                                                  
  *USP8*                                                      Corticotroph adenomas                                        Dominant gain of function mutations                                           ([@bib95], [@bib57])

###### 

Mouse models of pituitary neoplasia.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Tumour type                                                                                             Tumour site                                                                         Syndrome/Disorder                                                         Mouse model (gene -- method)                                                   Gender phenotype                                                                   Reference
  ------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------- ------------------------------------------------------------------------- ------------------------------------------------------------------------------ ---------------------------------------------------------------------------------- -------------
  **Prolactinoma** (secreting prolactin)                                                                  Isolated                                                                            Carney Complex                                                            ***Prkar1a*** --\                                                              \_\_                                                                               ([@bib132])
                                                                                                                                                                                                                                                                        Tissue-specific homozygous knockout                                                                                                                               

  Acromegaly/\                                                                                            ***Ghrh*** --\                                                                      \_\_                                                                      ([@bib6], [@bib7])                                                                                                                                                
  Gigantism                                                                                               Transgenic over-expression                                                                                                                                                                                                                                                                                                      

  Non-syndromic                                                                                           ***Prl*** --\                                                                       Female only                                                               ([@bib27])                                                                                                                                                        
                                                                                                          Heterozygous and homozygous knockout                                                                                                                                                                                                                                                                                            

  ***Prlr*** --\                                                                                          Male and female                                                                     ([@bib102])                                                                                                                                                                                                                                 
  Homozygous knockout                                                                                                                                                                                                                                                                                                                                                                                                                     

  ***TGFα*** -\                                                                                           Females only                                                                        ([@bib79])                                                                                                                                                                                                                                  
  Tissue-specific transgenic\                                                                                                                                                                                                                                                                                                                                                                                                             
  Over-expression                                                                                                                                                                                                                                                                                                                                                                                                                         

  *ptd*-***FGFR4*** --\                                                                                   Male and female                                                                     ([@bib33])                                                                                                                                                                                                                                  
  Tissue-specific transgenic\                                                                                                                                                                                                                                                                                                                                                                                                             
  Over-expression                                                                                                                                                                                                                                                                                                                                                                                                                         

  ***Prop1*** --\                                                                                         Female only                                                                         ([@bib32], [@bib28])                                                                                                                                                                                                                        
  Tissue specific transgenic\                                                                                                                                                                                                                                                                                                                                                                                                             
  Over-expression                                                                                                                                                                                                                                                                                                                                                                                                                         

  ***Drd2*** --\                                                                                          Females only                                                                        ([@bib61], [@bib8])                                                                                                                                                                                                                         
  Homozygous knockout                                                                                                                                                                                                                                                                                                                                                                                                                     

  ***Cyclin E*** --\                                                                                      \_\_                                                                                ([@bib98])                                                                                                                                                                                                                                  
  Tissue-specific transgenic over-expression                                                                                                                                                                                                                                                                                                                                                                                              

  Multiple                                                                                                MEN1                                                                                ***Men1*** --\                                                            Higher incidence in females                                                    ([@bib25], [@bib14], [@bib15], [@bib17], [@bib72], [@bib73], [@bib50], [@bib67])   
                                                                                                                                                                                              Heterozygous knockout                                                                                                                                                                                                                       

  ***Men1*** --\                                                                                          Higher incidence in females                                                         ([@bib18], [@bib26])                                                                                                                                                                                                                        
  Tissue-specific homozygous knockout                                                                                                                                                                                                                                                                                                                                                                                                     

  Non-syndromic                                                                                           ***Pttg***:***Rb*** --\                                                             Male and female\                                                          ([@bib30], [@bib21])                                                                                                                                              
                                                                                                          Tissue-specific transgenic *Pttg* over-expression: Heterozygous ***Rb*** knockout   *NB Pttg* knockout x *Rb* knockout is protective for pituitary adenomas                                                                                                                                                                     

  **p19** --\                                                                                             Male and female                                                                     ([@bib10])                                                                                                                                                                                                                                  
  Homozygous knockout                                                                                                                                                                                                                                                                                                                                                                                                                     

  ***Hmga1*** --\                                                                                         Higher incidence in females                                                         ([@bib35])                                                                                                                                                                                                                                  
  Transgenic over- expression                                                                                                                                                                                                                                                                                                                                                                                                             

  ***Hmga2*** --\                                                                                         Higher incidence in females                                                         ([@bib34])                                                                                                                                                                                                                                  
  Transgenic over- expression                                                                                                                                                                                                                                                                                                                                                                                                             

  ***AVP***-**SV40 large T antigen** --\                                                                  \_\_                                                                                ([@bib111])                                                                                                                                                                                                                                 
  Transgenic expression                                                                                                                                                                                                                                                                                                                                                                                                                   

  **Gonadotrophinoma** (secreting follicle stimulating hormone, lutenising hormone, or non-functioning)   Isolated                                                                            Non-syndromic                                                             ***FSHβ***-**SV40 temperature sensitive T antigen** --Transgenic expression    Male only                                                                          ([@bib65])

  **Pttg** --\                                                                                            Male and Female                                                                     ([@bib30], [@bib1])                                                                                                                                                                                                                         
  Tissue-specific transgenic over-expression                                                                                                                                                                                                                                                                                                                                                                                              

  ***Prop1*** --\                                                                                         Female only                                                                         ([@bib32], [@bib28])                                                                                                                                                                                                                        
  Tissue-specific transgenic\                                                                                                                                                                                                                                                                                                                                                                                                             
  Over-expression                                                                                                                                                                                                                                                                                                                                                                                                                         

  ***Cyclin E*** --\                                                                                      \_\_                                                                                ([@bib98])                                                                                                                                                                                                                                  
  Tissue-specific transgenic over-expression                                                                                                                                                                                                                                                                                                                                                                                              

  Multiple                                                                                                MEN1                                                                                ***Men1*** --\                                                            Higher incidence in females                                                    ([@bib25], [@bib14], [@bib15], [@bib17], [@bib72], [@bib73], [@bib50], [@bib67])   
                                                                                                                                                                                              Heterozygous knockout                                                                                                                                                                                                                       

  Non-syndromic                                                                                           ***Pttg***:***Rb*** --\                                                             Male and female\                                                          ([@bib30], [@bib21])                                                                                                                                              
                                                                                                          Tissue-specific transgenic *Pttg* over-expression: Heterozygous *Rb* knockout       *NB Pttg* knockout x *Rb* knockout is protective for pituitary adenomas                                                                                                                                                                     

  **p19** --\                                                                                             Male and female                                                                     ([@bib10])                                                                                                                                                                                                                                  
  Homozygous knockout                                                                                                                                                                                                                                                                                                                                                                                                                     

  **Somatotrophinoma** (secreting growth hormone)                                                         Isolated                                                                            FIPA                                                                      ***Aip*** --\                                                                  Male and female                                                                    ([@bib94])
                                                                                                                                                                                                                                                                        Heterozygous knockout                                                                                                                                             

  Carney Complex                                                                                          ***Prkar1a*** --\                                                                   \_\_                                                                      ([@bib132])                                                                                                                                                       
                                                                                                          Tissue-specific homozygous knockout                                                                                                                                                                                                                                                                                             

  Acromegaly/\                                                                                            ***Ghrh*** --\                                                                      \_\_                                                                      ([@bib6], [@bib7])                                                                                                                                                
  Gigantism                                                                                               Transgenic over- expression                                                                                                                                                                                                                                                                                                     

  Non-syndromic                                                                                           ***Prop1*** --\                                                                     Female only                                                               ([@bib32], [@bib28])                                                                                                                                              
                                                                                                          Tissue-specific transgenic\                                                                                                                                                                                                                                                                                                     
                                                                                                          over-expression                                                                                                                                                                                                                                                                                                                 

  ***Cyclin E*** --\                                                                                      \_\_                                                                                ([@bib98])                                                                                                                                                                                                                                  
  Tissue-specific transgenic over-expression                                                                                                                                                                                                                                                                                                                                                                                              

  Multiple                                                                                                MEN1                                                                                ***Men1*** --\                                                            Higher incidence in females                                                    ([@bib25], [@bib14], [@bib15], [@bib17], [@bib72], [@bib73], [@bib50], [@bib67])   
                                                                                                                                                                                              Heterozygous knockout                                                                                                                                                                                                                       

  Non-syndromic                                                                                           ***Pttg***:***Rb*** --\                                                             Male and female\                                                          ([@bib30], [@bib21])                                                                                                                                              
                                                                                                          Tissue-specific transgenic *Pttg* over-expression: Heterozygous *Rb* knockout       *NB Pttg* knockout x *Rb* knockout is protective for pituitary adenomas                                                                                                                                                                     

  **p19** --\                                                                                             Male and female                                                                     ([@bib10])                                                                                                                                                                                                                                  
  Homozygous knockout                                                                                                                                                                                                                                                                                                                                                                                                                     

  ***Hmga1*** --\                                                                                         Higher incidence in females                                                         ([@bib35])                                                                                                                                                                                                                                  
  Transgenic over- expression                                                                                                                                                                                                                                                                                                                                                                                                             

  ***Hmga2*** --\                                                                                         Higher incidence in females                                                         ([@bib34])                                                                                                                                                                                                                                  
  Transgenic over- expression                                                                                                                                                                                                                                                                                                                                                                                                             

  ***AVP***-**SV40 large T antigen** --\                                                                  \_\_                                                                                ([@bib111])                                                                                                                                                                                                                                 
  Transgenic over-expression                                                                                                                                                                                                                                                                                                                                                                                                              

  **Corticotrophinoma** (secreting adrenocorticotropic hormone)                                           Isolated                                                                            Acromegaly/\                                                              **p18** --\                                                                    Male and female                                                                    ([@bib40])
                                                                                                                                                                                              Gigantism                                                                 Homozygous knockout                                                                                                                                               

  **p18**:**p27** --\                                                                                     Male and female\                                                                    ([@bib40])                                                                                                                                                                                                                                  
  Homozygous p18 knockout: Homozygous p27 knockout                                                        Accelerated rate of adenomas                                                                                                                                                                                                                                                                                                    

  Cushing\'s                                                                                              ***PyLT*** --\                                                                      Male and female                                                           ([@bib53])                                                                                                                                                        
                                                                                                          Transgenic over- expression                                                                                                                                                                                                                                                                                                     

  ***Crh*** --\                                                                                           Male and female                                                                     ([@bib112])                                                                                                                                                                                                                                 
  Transgenic over- expression                                                                                                                                                                                                                                                                                                                                                                                                             

  ***Crh*** --\                                                                                           Male and female                                                                     ([@bib13])                                                                                                                                                                                                                                  
  Heterozygous gain-of-function mutation (ENU)                                                                                                                                                                                                                                                                                                                                                                                            

  Non-syndromic                                                                                           ***Pttg***:***Rb*** --\                                                             Male and female\                                                          ([@bib30], [@bib21])                                                                                                                                              
                                                                                                          Tissue-specific transgenic *Pttg* over-expression: Heterozygous *Rb* knockout       *NB Pttg* knockout x *Rb* knockout is protective for pituitary adenomas                                                                                                                                                                     

  Multiple                                                                                                Non-syndromic                                                                       ***Rb***:***Ini1*** --\                                                   \_\_\                                                                          ([@bib48])                                                                         
                                                                                                                                                                                              Heterozygous *Rb* knockout: *Heterozygous*\                               Accelerated carcinoma development                                                                                                                                 
                                                                                                                                                                                              *Ini1* knockout                                                                                                                                                                                                                             

  **SV40 large T antigen** --Transgenic expression under *Pomc* promoter                                  \_\_                                                                                ([@bib74])                                                                                                                                                                                                                                  

  ***AVP***-**SV40 large T antigen** --\                                                                  \_\_                                                                                ([@bib111])                                                                                                                                                                                                                                 
  Transgenic over- expression                                                                                                                                                                                                                                                                                                                                                                                                             

  **Thyrotrophinoma** (secreting thyroid stimulating hormone)                                             Isolated                                                                            Carney Complex                                                            ***Prkar1a*** --\                                                              \_\_                                                                               ([@bib132])
                                                                                                                                                                                                                                                                        Tissue-specific homozygous knockout                                                                                                                               

  Acromegaly/\                                                                                            ***Ghrh*** --\                                                                      \_\_                                                                      ([@bib6], [@bib7])                                                                                                                                                
  Gigantism                                                                                               Transgenic over- expression                                                                                                                                                                                                                                                                                                     

  Non-syndromic                                                                                           ***p18***:*α****SU*** --\                                                           \_\_                                                                      ([@bib71])                                                                                                                                                        
                                                                                                          Homozygous p18 knockout: Homozygous\                                                                                                                                                                                                                                                                                            
                                                                                                          *αSU* knockout                                                                                                                                                                                                                                                                                                                  

  ***Prop1*** --\                                                                                         Female only                                                                         ([@bib32], [@bib28])                                                                                                                                                                                                                        
  Tissue-specific transgenic\                                                                                                                                                                                                                                                                                                                                                                                                             
  over-expression                                                                                                                                                                                                                                                                                                                                                                                                                         

  Multiple                                                                                                Non-syndromic                                                                       ***AVP***-**SV40 large T antigen** --\                                    \_\_                                                                           ([@bib111])                                                                        
                                                                                                                                                                                              Transgenic over- expression                                                                                                                                                                                                                 

  **Craniopharyngiomas**                                                                                  Isolated                                                                            Non-syndromic                                                             ***Ctnnb1*** --\                                                               \_\_                                                                               ([@bib43])
                                                                                                                                                                                                                                                                        Tissue-specific knockout of exon 3, rendering *Ctnnb1* degradation resistant                                                                                      

  **Undefined** adenoma subtype                                                                           Isolated                                                                            Non-syndromic                                                             ***Bmi1*** --\                                                                 \_\_                                                                               ([@bib128])
                                                                                                                                                                                                                                                                        Tissue-specific transgenic\                                                                                                                                       
                                                                                                                                                                                                                                                                        over-expression                                                                                                                                                   

  Multiple                                                                                                MEN4                                                                                ***Cdkn1b*** --\                                                          Male and female - females infertile                                            ([@bib63], [@bib83], [@bib37])                                                     
                                                                                                                                                                                              Homozygous knockout                                                                                                                                                                                                                         

  ***Cdkn1b*** --\                                                                                        \_\_                                                                                ([@bib16])                                                                                                                                                                                                                                  
  Homozygou*s* inactivating mutation knockin                                                                                                                                                                                                                                                                                                                                                                                              

  Non-syndromic                                                                                           ***Cdk4*** --\                                                                      Male and female                                                           ([@bib108])                                                                                                                                                       
                                                                                                          mutation (rendering protein insensitive to INK4 inhibitors) knockin                                                                                                                                                                                                                                                             

  ***Cdk4***:***Cdkn1b*** -- Transgenic *Cdk4* mutation knockin: Homozygous *Cdkn1b* knockout             \_\_                                                                                ([@bib109])                                                                                                                                                                                                                                 

  ***Men1***:***Cdk2*** --\                                                                               Male and female                                                                     ([@bib45])                                                                                                                                                                                                                                  
  Heterozygous *Men1* knockout: homozygous *Cdk2* knockout                                                                                                                                                                                                                                                                                                                                                                                

  **Cyclin E**:**p27** --\                                                                                \_\_\                                                                               ([@bib98])                                                                                                                                                                                                                                  
  Tissue-specific transgenic Cyclin E over-expression: Homozygous p27 knockout                            Increased adenoma size, proliferation and frequency                                                                                                                                                                                                                                                                             

  ***Ink4c***:***Arf*** --\                                                                               Male and female                                                                     ([@bib136])                                                                                                                                                                                                                                 
  Homozygous *Ink4c* knockout: Homozygous\                                                                                                                                                                                                                                                                                                                                                                                                
  *Arf* knockout                                                                                                                                                                                                                                                                                                                                                                                                                          

  ***Rb*** --\                                                                                            \_\_                                                                                ([@bib55])                                                                                                                                                                                                                                  
  Heterozygous knockout                                                                                                                                                                                                                                                                                                                                                                                                                   

  ***Rb*** --\                                                                                            \_\_                                                                                ([@bib122], [@bib123])                                                                                                                                                                                                                      
  Tissue-specific homozygous knockout                                                                                                                                                                                                                                                                                                                                                                                                     

  ***Rb***:***Arf*** --\                                                                                  \_\_\                                                                               ([@bib118])                                                                                                                                                                                                                                 
  Heterozygous *Rb* knockout: Homozygous *Arf* knockout                                                   Accelerated tumour development                                                                                                                                                                                                                                                                                                  

  ***Rb***:**p53** --\                                                                                    \_\_                                                                                ([@bib52])                                                                                                                                                                                                                                  
  Heterozygous *Rb* knockout: Heterozygous and homozygous p53 knockout                                                                                                                                                                                                                                                                                                                                                                    
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

- = not defined; MEN1 -- multiple endocrine neoplasia type 1; MEN4 - multiple endocrine neoplasia type 4; FIPA -- familial isolated pituitary adenomas.
